Wednesday, September 23, 2020
wellness India Expo
Home Tags Biocon

Tag: Biocon

Vasudev Tribhuvan joins Wellthy Therapeutics as VP-Partnerships & Alliances

Vasudev’s previous role was at Biocon, where he was the Senior Director, Marketing and led strategic initiatives for the metabolic unit while guiding the team on patient programs..............

US FDA approves Mylan & Biocon’s biosimilar, Fulphila

Second FDA-approved biosimilar through the Mylan-Biocon collaboration,, Fulphila is expected to be the first biosimilar pegfilgrastim available in the U.S. to help patients with nonmyeloid cancers reduce the risk of infection...............

Shrikumar Suryanarayan of Sea6Energy takes over as ABLE President

A new team of elected Executive Council, led by Mr Shrikumar Suryanarayan, chairman of Sea6Energy, as President has taken charge at the Association of Biotechnology Led Enterprises (ABLE) on April 1, 2018............

15th edition of BioAsia 2018 concludes with highest ever participation

This time the event witnessed highest ever participation of 1,757 delegates from bioscience sector besides 1,250 partnering meetings conducted on the sidelines leading to key strategic decisions...........

BioAsia 2018 witnesses intense deliberations over creating innovative bioscience ecosystem

The event that pitched Telangana as a strong contender to become the Gateway of India for biotechnology and life sciences, witnessed commitment from Biocon (Syngene) to set up its R&D unit in the state and generate 1500 new jobs...........

Biocon & Mylan’s biosimilar ‘Trastuzumab’ gets approval from Brazilian regulator

Co-developed by Biocon and Mylan, this is the first biosimilar Trastuzumab to be approved in Brazil and is indicated for the treatment of overexpressing HER2­positive metastatic breast cancer. The product will be marketed by the Libbs Farmaceutica........

USFDA approves Mylan & Biocon´s biosimilar for breast, gastric cancers

Mylan anticipates potentially being the first company to provide patient access to a biosimilar to Herceptin, representing a significant milestone for Mylan, Biocon and the overall healthcare system........

Biocon confident of resolving issues with USFDA over biosimilar ‘pegfilgrastim’

While the company is set to launch proposed biosimilar, Pegfilgrastim in the United States market, the US Food and Drug Administration has issued Complete Response Letter (CRL) to it seeking more data on the cancer drug..............

Biocon & Mylan’s proposed biosimilar ‘Trastuzumab’ gets USFDA nod

The US-FDA Oncologic Drugs Advisory Committee has unanimously recommended approval of Mylan and Biocon’s proposed cancer targeting biosimilar, Trastuzumab.............

Biocon closes financial year 2017 with a strong revenue growth of...

Biocon reported a revenue of Rs 974 crore for quarter 4 of FY17 and a revenue of Rs 4,079 Cr for the entire FY17...........